ist noch jemand in amarin (amrn) investiert?

news gabe es in letzter zeit keine. ich werde weiter halten. vielleicht kommt der ausbruch ja noch.

grüße

 

Kannste bedenkenlos halten.

Is so ne Aktie die immer wieder nen starken up-move macht.




Grüße         Reiny

 

danke für deine einschätzung. bist du auch investiert oder watchlist?

grüße  

Bin nicht investiert, aber vielleicht kauf ich mich schon sehr bald ein.










Grüße         Reiny  

sagt Knobias.com  

Heute schwenke ich für euch mal zu Amarin!Zunächst aber einmal eine kurze Vorstellung: Ich bin seit 20 Jahren Aktionär und Anleger und komme aus Wien.
Bevor ich nun einen Kurzkommentar zu Amarin gebe, hier mal News für euch von vor einigen Tagen:

LONDON, February 12 /PRNewswire-FirstCall/ -- Amarin Corporation plc today announced that it has reached a full and final agreement with Elan Corporation plc. and certain of its subsidiaries ("Elan") regarding the settlement of outstanding financial obligations. The amount currently required to discharge these obligations stands at approximately $24.4 million.

Amarin will pay Elan approximately $17.2 million in cash, plus a further payment of $1 million on the successful completion of the Zelapar safety trials to discharge these obligations. Amarin will also issue to Elan a $5 million 5-year loan note with capital repayment as follows:

- $1.5 million January 2006 - $1.5 million July 2007 - $2 million January 2009

At Elan''s option, the loan note can be repaid from proceeds Amarin receives from a $5 million milestone payable by Valeant Pharmaceuticals International on the NDA approval of Zelapar. The loan note is redeemable by Amarin at any time and carries an interest rate of 8%.

Additionally, Amarin will issue 500,000 warrants to Elan priced at the average market closing price for the previous 30 days prior to closing. Elan''s fully diluted ownership in Amarin increases from 25.9% to 28.0%

The agreement is conditional upon closing of the sale of Amarin Pharmaceuticals Inc. and the majority of its U.S. product portfolio.

For press releases and other corporate information, visit our website at http://www.amarincorp.com/.

Statements in this press release that are not historical facts are forward-looking statements that involve risks and uncertainties which may cause the Company''s actual results in future periods to be materially different from any performance suggested herein. Such risks and uncertainties include, without limitation, the uncertainty of entering into and consummating a definitive agreement on terms acceptable to the parties, the inherent uncertainty of pharmaceutical research, product development and commercialisation, the impact of competitive products and patents, as well as other risks and uncertainties detailed from time to time in periodic reports. For more information, please refer to Amarin Corporation''s Annual Report for 2002 on Form 20-F and its Form 6-Ks as filed with the U.S. Securities and Exchange Commission. The company assumes no obligation to update information on its expectations.

Amarin Corporation Plc

© PR Newswire


Klicken Sie hier, um weitere aktuelle Nachrichten zum Unternehmen zu finden:

ELAN CORPORATION
 

Nun, ihr habt es gelesen? Well, Amarin ist aus drei Pharmawerten hervorgegangen und hat ihren Hauptsitz in London. Hauptaktionär ist die Firma Elan, eine Pharmacompany mit Sitz in Irland, die jetzt nochmal ihren Anteil an AMRN aufgestockt hat, und zwar von 25 Prozent auf ca. 28%! Citigroup hält 5 %!
Amarin bekommt nun folgendes von Elan und Valeant: 38 Mio.USD bertrag einer Hauptgruppe an Amarin Produkten in den USA, wie z.B die Rechte an Zelarpar, einem 100 Mio. USD Blockbuster. Sollte Zelapar einen gewisse Verkaufsschwelle erreichen, werden weitere 8 Mio. USD bezahlt. 10 Mio USD Entwicklungskosten werden übernommen. Elan gibt Amarin darüber hinaus einen Kredit von weiteren 5 Mio. Dollar auf mehrere Jahre. Dafür verpflichtet sich Amarin einen bestehenden Kredit an Elan entgültig zurückzuzahlen, was bereits passiert ist. Aber, Elan hat enorm Schulden nachgelassen. Ich habe es mir mal nachgerechnet: So in der GHrößenordnung von 4-5 USD per Share! Amarin ist zudem weiter als Supervisor tätig für Zelapar. Und was noch wichtiger ist: Lax 101, und alle Rechte darauf (ein Mittel gegen Huntigston Desease) bleiben bei AMRN! Ist natürlich alles noch in Entwicklung, kommt aber bald zur Marktreife! Nächste Woche stelle ich euch eine wesentlich umfassendere Analyse rein, das war jetzt nur mal ein kurzer Rekurs. Aber zum Fazit: Kursziel USD 5,50 auf Sicht 12 Monate! Das sage nicht ich, sonern JM. Dutton Associates, ein kleines aber feines Investmenthaus aus San Francisco. Die Analyse gibst auch dort! Kauft an der Nasdaq, in Berlin sind keine Umsätzte. Noch was: Es war Insidertrading, warum der Wert explodiert ist, mix anderes. Jetzt dauerts etwas, dann hebt Amarin wieder ab, und dann dauerhaft. Amarin ist Schuldenfrei (fast), was will man mehr! Strong Buy

Euer Ostarrichi  

Also, nicht vergessen, kauft euch schon mal ein und lest meine Postings Analyse zu Amarin!

Euer Ostarrichi  

schön, wenn du weiter deine infos über amarin ins board stellst. ich habe immer noch eine position im depot.

grüße  

Mache ich, mußt nur etwas Geduld mit mir haben! Gut Ding braucht Weile, und ich will es seriös machen.
Sollte Amarin weiter fallen, kaufe ich nach! Aber ich warte noch paar Tage zu. Man hat ja manchmal den Eindruck, daß manche blind sind und gute Aktien nicht erkennen. Der Deal mit Valeant und Elan war jedenfalls genial! Die schieben hin und her und sparen so Steuern!:)) Kursziel bleibt USD 5.50 oder sogar mehr. Wird schon!
Kaufst auch nach, wenn es noch billiger wird?

Grüße

Ostarrichi

PS: Und vergiß nicht, AMRN notiert immerhin am Trading Floor und nicht OTC! Bei BK von lächerlichen 30 Mio. USD sogar unter Deal-Kurs! Ein Witz, echt!:))  

 

Hi Ramses und die anderen,

heute ist Nachkauftag!:)))))

Main Uptade kommt auch bald.

LG

Ostarrichi  

 

Hi,

weil es schön langsam enorm unterbewertet ist das Unternehmen und auch der Chart total überverkauft wirkt!
Hier leiß mal vom 4 Qartal:

Press Information


Amarin Corporation Reports Fourth Quarter and 2001 Financial Results



Revenues Increased 118 Percent to $56.9 Million in 2001

Company Achieves Earnings per ADS of $0.28 (before exceptional charges) for the Fourth Quarter and Earnings per ADS of $1.28 (before exceptional charges) for Fiscal 2001

LONDON, United Kingdom, February 11, 2002-- Amarin Corporation plc (NASDAQ: AMRN) today reported that total revenues grew 31 percent to $17.1 million for the fourth quarter ended December 31, 2001. For the quarter, the Company achieved net income of $3.2 million (before exceptional charges) and diluted earnings per American Depository Share (ADS) of $0.28 (before exceptional charges). This is compared with revenues of $13.0 million, net income of $3.1 million and diluted earnings per ADS of $0.30 for the same period a year ago. The fourth quarter of 2000 benefited from $8.7 million of sales and $3.9 million in net income relating to discontinued operations.

For the fiscal year 2001, total revenues more than doubled to $56.9 million, compared with $26.2 million in 2000. Net income (before exceptional charges) increased more than 500 percent in 2001 to $14.4 million and diluted earnings per ADS (before exceptional charges) increased 341 percent to $1.28. This is compared with net income of $2.4 million and diluted earnings per ADS of $0.29 in 2000. All per share comparisons have been impacted by the increased weighted average number of diluted ordinary shares for both the fourth quarter of 2001 and the year in its entirety. This increase reflects the full effect of the Company's $11.5 million private equity placement in June 2000.

"Unquestionably, 2001 represented the most successful year in Amarin's history," said Rick Stewart, chief executive officer. "It was a year in which we achieved significant milestones. By acquiring the rights to Permax® and a purchase option for Zelapar™, we succeeded in establishing a strategic franchise in the therapeutic area of Parkinson's disease. By adding Zelapar™ to a pipeline already possessing LAX-101, Amarin is now positioned to potentially become a leader in the field of movement disorder. The Company successfully launched a specialty sales force dedicated to neurology. Importantly, we also invested in the infrastructure necessary for the eventual commercialisation of our late-stage development pipeline."

Permax® (pergolide mesylate tablets) is a dopamine receptor agonist indicated as adjunctive therapy in the management of Parkinson"s disease. Zelapar™ (Zydis® selegiline tablets), an MAO-B inhibitor, is a potential treatment for Parkinson's disease. A New Drug Application for Zelapar™ is expected to be submitted to the U.S. Food and Drug Administration in the first half of 2002. Amarin gained exclusive U.S. marketing, sales and distribution rights to Permax®, and a purchase option for Zelapar™ in May 2001. LAX-101 is a potential treatment for Huntington's disease that is currently in Phase III clinical trials.

In the fourth quarter of 2001, the Company recorded an exceptional charge within operating expenses of $18.1 million in accordance with FRS 3 (UK GAAP) and FASB 142 (U.S. GAAP). The exceptional charge relates to the partial amortization of the U.S. marketing, sales and distribution rights associated with Permax®. The Company also recognized an exceptional one-time charge of $1.3 million on the disposition of its transdermal patch product development business in Argentina. After these exceptional charges, the Company reported a net loss of $16.2 million and loss per ADS of $1.39 for the fourth quarter of 2001. For the year, the Company reported a net loss of $5.1 million and loss per ADS of $0.46.

In 2001, product revenues were $46.5 million, of which Permax contributed $29.6 million. Legacy products (non-therapeutically focused, directly marketed products) contributed the remaining $16.9 million. Amarin Development achieved revenues of $6.1 million, an increase of 11 percent, resulting in a return to profitability for this business. Revenues from Amarin Technologies in Argentina have been included in the Company"s financial results until the date of its disposal in December 2001 and totalled $1.5 million. Amarin Corporation contributed revenues of $2.8 million.

The increase in direct cost of sales in 2001 predominantly represents the increased cost of goods associated with the increased revenues resulting from Permax® sales. Selling, general and administrative expense more than doubled to $15 million in 2001. This increase resulted primarily from the expansion of the Company's sales and marketing infrastructure in the U.S. and the launch of the Company's 24-member U.S. neurology sales force. The decrease in research and development expense for the year resulted, in part, from the continued rationalisation of research and development operations in Sweden. Under Amarin's strategic development partnering agreements, research and development expense for Amarin's Phase III pipeline products are principally the responsibility of Amarin's development partners. Amarin does not have any interests in joint venture vehicles or off-balance sheet entities.

Since the end of the third quarter of 2001, Amarin Corporation:

recruited and launched a 24-person specialty neurology sales force;
strengthened senior management by recruiting Michael M. Wess, M.D. as vice president of medical and scientific affairs for Amarin Pharmaceuticals, Inc., the pharmaceutical development and marketing subsidiary of Amarin Corporation plc;
sold its transdermal patch product development business in South America, completing the planned divestiture of all its transdermal research and development facilities; and
announced that positive results of two separate Phase II studies of LAX-101 (and a LAX-101 prototype) were published in the January 21 issue of NeuroReport. LAX-101 is a novel and proprietary potential treatment for Huntington's disease which is currently in Phase III clinical trials in the U.S. and internationally.
Amarin Corporation plc is a specialty pharmaceutical company focused on neurology and pain management. The company plans to become a leader in these therapeutic categories by providing innovative products and solutions that address significant unmet medical needs. For press release and other Company information, visit our website at www.amarincorp.com.

Amarin Corporation plc

Period Ended  December 31st, 2001

SELECTED DATA (UK GAAP - UNAUDITED)



INCOME STATEMENT Three months ended
December 31st Twelve months ended
December 31st
2000
$'000 2001
$'000 2000
$'000 2001
$'000

REVENUE
Licensing & Development Fees 733 325 1,410 2,143
Royalties & Product Sales 3,608 15,412 16,126 51,602
Revenues from discontinued business 8,664 1,330 8,664 3,237
Total Revenues 13,005 17,067 26,200 56,982

OPERATING EXPENSES
Direct Costs 926 6,853 5,216 21,444
Research & Development 2,496 1,022 5,745 4,134
Selling, General & Administrative 1,095 4,904 5,789 12,513
Operating expenses from discontinued business 1,733 1,630 1,733 2,572
Amortisation of intangible fixed assets 441 (410) 1,764 2,273
Share option compensation 542 - 1,580 -
Provision for terminating discontinued business 3,149 (1,070) 3,149 (1,070)
Total Expenses
10,382 12,929 24,976 41,866

 
OPERATING INCOME before exceptional cost 2,623 4,138 1,224 15,116
Exceptional amortisation of Permax sales rights - 18,123 - 18,123
 
OPERATING INCOME/(LOSS) after exceptional cost 2,623 (13,985) 1,224 (3,007)

Interest & Investment Income (net) 329 (6) 524 365
Foreign exchange (loss)/gain - (451) - (451)
Exceptional gain/(loss) on disposal of discontinued business 306 (1,299) 1,134 (1,299)

 
INCOME/(LOSS) BEFORE TAXES 3,258 (15,741) 2,882 (4,392)

Income Taxes Paid 135 402 342 485
Dividends payable 49 46 185 180
NET INCOME/(LOSS) FOR PERIOD 3,074 (16,189) 2,355 (5,057)
 
NET INCOME FOR PERIOD BEFORE EXCEPTIONAL CHARGES 3,074 3,233 2,355 14,365
 
WEIGHTED AVERAGE NUMBER OF DILUTED SHARES - Thousands 100,844 117,562 80,834 112,545
 
INCOME PER ADS (DILUTED) Prior to Exceptional Charges 0.30 0.28 0.29 1.28
 
INCOME/(LOSS) PER ADS (DILUTED) from Net Income 0.30 (1.39) 0.29 (0.46)
 

SELECTED BALANCE SHEET DATA $'000
Working capital (inc short term debt) (12,389)
Cash 30,109
Accounts receivable 7,650
Total assets 90,721
Long-term obligations (7,355)
Stockholders' equity 29,670


All figures are in round thousands except 'Income/(Loss) Per ADS'
The company's ratio of ADS's to ordinary shares is 1:10  

Hi,

habe eigentlich was anderes einfügen wollen, nicht vom Vorjahr!:)) Kann man leider nimmer löschen! Aber egal: Es ist unterbewertet!
Ich kauf heute 2,000 Stück nach! Habe dann 9000 Stück.

Ostarrichi  

Hi,

wenn Du mir eine Mail gibst, sende ich Dir die Analyse! Geht nur mit Mail, weil ich Acrobat Reader nicht kopieren kann, leider.
Ist sicher interessant zum lesen.

Ostarrichi  

Hi,

Amarin zeigt Bodenbildung!

Ostarrichi


PS: Analyse kannst per Mail haben. Ist super!  

Press Information


Amarin Corporation Announces Asset Sale To Valeant Pharmaceuticals International



--Amarin Retains Exclusive U.S. Rights to LAX-101 for Huntington’s Disease—



LONDON, United Kingdom, February 12, 2004 – Amarin Corporation plc (NASDAQ: AMRN) today announced that it has entered into a definitive agreement with Valeant Pharmaceuticals International (Valeant) (NYSE: VRX) whereby Valeant will acquire its U.S.-based subsidiary, Amarin Pharmaceuticals, Inc. and a majority of its U.S. products in a cash transaction valued at approximately $46 million, including $8 million in milestone payments.   In addition, Valeant will assume certain other outstanding liabilities, including Amarin’s obligation to make a milestone payment to Elan of $10 million, if sales of Zelapar reach a certain level.

Under the terms of the transaction, Valeant will make an initial payment of $38 million to Amarin Corporation for the company’s interests in Amarin Pharmaceuticals Inc. along with the rights to Amarin’s product portfolio, which includes Permax®, a product indicated for the adjunct treatment of Parkinson’s disease; a primary care product portfolio with a broad range of indications and Zelapar™, an in-licensed, late-stage development product for the adjunct treatment of Parkinson’s disease, which has received an approvable letter from the Food & Drug Administration (FDA). The agreement calls for Valeant to make a milestone payment to Amarin Corporation of $3 million following the successful completion of the previously announced Zelapar clinical safety studies, and a further milestone of $5 million upon final approval of the Zelapar NDA by the FDA.

Amarin Corporation will retain responsibility for certain activities during a transition period post closing of the transaction, including the supervision of the Zelapar clinical safety studies and inventory management among other obligations. Amarin will be responsible for funding costs and liabilities relating to these activities totaling $12.5 million at closing.  

Amarin will retain exclusive U.S. rights to LAX-101, a compound in development for the treatment of Huntington’s Disease.  Following the transaction, Amarin Corporation will concentrate on working with Laxdale Limited, the developer of LAX-101, to progress the compound through additional Phase III clinical studies.  LAX-101 has undergone one Phase III trial, which identified promising results, and preparations are underway for an additional Phase III study in the United States.

Rick Stewart, chief executive officer of Amarin Corporation, stated, “This transaction permits Amarin to resolve its immediate financial obligations, including a payment due this quarter to Elan Corporation, allowing the company to focus on bringing significant compounds to market and restoring shareholder value. Amarin’s future efforts will concentrate on progressing the studies for LAX-101, selectively in-licensing late stage development compounds and acquiring promising compounds where available.”

Amarin anticipates that the net proceeds of the transaction will be sufficient to pay the financial obligations due to Elan Corporation.

Amarin and Valeant have received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. Closing of the transaction remains subject to customary contingencies in a transaction of this nature, including the receipt of any required third party approvals. Amarin was advised by SG Cowen Securities Corp.

For press releases and other corporate information, visit our website at http://www.amarincorp.com.  
    Contact Information

Rick Stewart
Chief Executive Officer
Amarin Corporation plc
Phone: +44 (0) 20 7907 2440
Email: rick.stewart@amarincorp.com
- - - - - - - - - - - - - - - - - - - - -

Ian Garland
Chief Financial Officer
Amarin Corporation plc
Phone: +44 (0) 20 7907 2444
Email: ian.garland@amarincorp.com
- - - - - - - - - - - - - - - - - - - - -



Statements in this press release that are not historical facts are forward-looking statements that involve risks and uncertainties which may cause the Company’s actual results in future periods to be materially different from any performance suggested herein. Such risks and uncertainties include, without limitation, the uncertainty of entering into and consummating a definitive agreement on terms acceptable to the parties, the inherent uncertainty of pharmaceutical research, product development and commercialization, the impact of competitive products and patents, as well as other risks and uncertainties detailed from time to time in periodic reports. For more information, please refer to Amarin Corporation’s Annual Report for 2002 on Form 20-F and its Form 6-Ks as filed with the U.S. Securities and Exchange Commission. The company assumes no obligation to update information on its expectations  
 

Press Information


Amarin Corporation Completes Asset Sale To Valeant Pharmaceuticals International



LONDON, United Kingdom, February 26, 2004 – Amarin Corporation plc (NASDAQ: AMRN) today announced that it has completed the sale of its U.S. based subsidiary, Amarin Pharmaceuticals, Inc. and a majority of its U.S. products to Valeant Pharmaceuticals International (Valeant) (NYSE: VRX). The terms of the transaction were substantially as previously announced on February 12. Under the terms of the merger, Amarin Pharmaceuticals, Inc. will become a wholly owned subsidiary of Valeant Pharmaceuticals International.

Amarin also announces that it has settled its financial obligations to Elan under the terms announced on February 12, 2004.

For press releases and other corporate information, visit our website at http://www.amarincorp.com.
 

 

 

limit 1,40 hat vorgestern nicht gegriffen. gestern für 1,35 rein.

grüße  

Ziemlich markteng momentan, viele Teilausführungen!:((

Habe jetzt 10,000 Stück! Was meinst, gibts endlich Rebound? Ist ja ein Kurs, mamamia...unter Buchwert! Und das an der Nasdaq, tssss....!:))

Ostarrichi

PS: Dein Kursziel?  

wenn wieder bewegung in die aktie kommt und keine negativen news anstehen, dann kann es von dem niveau aus ein verdoppler werden.

30 % bis 50 % wären auch sehr schön.

grüße  

Die Aktie ist ein Witz! Da bekommen die fast 40 Mio. USD Cash und die Restschulden gegen Elan werden erlassen, und dann sackt die Aktie so ab, obwohl es nur 18 Mio. Stück gibt und der cashbestand höher ist als der Wert aller Aktien an der Börse. Wenn das nicht primitiv ist, was dann. Kursziel USD 5,50! Irgendwann merken es auch die Blinden, daß da etwas nicht stimmen kann!:)) Leider war ich zu früh drinnen!:((

Aber jetzt ärgere ich mich über den Kurs voll, weil das ist ja ein kompletter Schwachsinn. Man müßte jetzt 25 % kaufen und dann laut lachen!

Ostarrichi

PS: 50 % sind nicht so schlecht! Freut mich, daß es noch jemand anderen außer mir gibt, der den Wert erkennt von Amarin!